Brad Margus has been tapped to co-chair the oversight board for the Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, a new, innovative program at the National Institutes of Health.

NeuroNEXT, will provide a robust, standardized, and expert network of 25 clinical centers across the USA to more quickly test treatments for adults and children with neurological disorders. It promises to alleviate some of the current bottlenecks in the development of new drugs for neurological disorders and could be useful to test promising therapies for A-T.

Oops! We could not locate your form.

Related News

Jul 19 @ 12:37 pm

N-Acetyl-L-Leucine Clinical Trial for A-T

IntraBio is conducting a clinical trial to test a product called N-Acetyl-L-Leucine in children and adults with A-T.

more
Jul 19 @ 12:37 pm

New Edition of “Caring for People with A-T” Published

A new edition of the "Caring for People with A-T" guide has been published!

more
Jul 19 @ 12:37 pm

Measles Prevention in A-T: Recommendations from Dr. Lederman

Dr. Lederman of the A-T Clinical Center provides recommendations to keep people with A-T from catching measles.

more
Jul 19 @ 12:37 pm

Gene Editing for A-T Grant Awarded

We are pleased to announce that funds have been awarded to a researcher with Johns Hopkins University.

more